Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Lane Building L-135, Stanford, CA 94305-5107, USA.
Stanford University, 450 Serra Mall, Stanford, CA 94305, USA.
Infect Dis Clin North Am. 2020 Jun;34(2):311-339. doi: 10.1016/j.idc.2020.02.006.
Herpesviruses such as herpes simplex virus (HSV) type 1 and 2, varicella-zoster virus (VZV), and cytomegalovirus (CMV) maintain lifelong latency in the host after primary infection and can reactivate periodically either as asymptomatic viral shedding or as clinical disease. Immunosuppression, including biologic therapy, may increase frequency and severity of herpesvirus reactivation and infection. Licensed biologics are reviewed regarding their risks of potentiating HSV, VZV, and CMV reactivation and infection. Approaches to prophylaxis against HSV, VZV, and CMV infection or reactivation are discussed.
单纯疱疹病毒(HSV) 1 型和 2 型、水痘-带状疱疹病毒(VZV)和巨细胞病毒(CMV)等疱疹病毒在初次感染后在宿主体内保持终身潜伏，并可周期性地重新激活，表现为无症状病毒脱落或临床疾病。免疫抑制，包括生物治疗，可能会增加疱疹病毒重新激活和感染的频率和严重程度。对这些已上市的生物制剂进行了评估，以了解其是否会增加 HSV、VZV 和 CMV 重新激活和感染的风险。本文还讨论了预防 HSV、VZV 和 CMV 感染或重新激活的方法。
